Category: Smith & Nephew
Royal Oak Medical Devices touts its 'repless' generic sales model, saying it can save its hospital customers more than $100,000 a year on their orthopedic implant spends.
Royal Oak Medical Devices says it can save its hospital customers more than $100,000 a year on their orthopedic implant spends, using its so-called 'repless' generic sales model.
Here's a look at some of the top legal news stories for medical device companies this week: Smith & Nephew gets in on Michelson Diagnostics Series B round; Diabetes: Valeritas registers $90m IPO; HeartFlow raises $36m for non-invasive FFR system; Bellerophon prices $60m IPO low, issues more shares; Rainbow Medical raises $25m for China ops
Smith & Nephew joins a $3.8 million Series B round for Michelson Diagnostics and its VivoSight OCT-based skin cancer detection device.
Smith & Nephew CEO Olivier Bohoun calls the 'no-frills' Syncera program, which replaces sales reps with an automated system, a growth driver but refuses to set expectations.
Regulators in the U.K. issue a medical device alert on Smith & Nephew's Renasys negative-pressure wound therapy device, following a field safety notice the company issued last October.
With 20 placements of Mako's surgical robots in the final quarter of 2014, Stryker CEO Kevin Lobo is confident in the $1.7 billion acquisition – and in Stryker's ability to integrate future acquisitions.
Stryker (NYSE:SYK) posted a stellar quarter of sales for the robotic surgical system it acquired in its $1.7 billion deal for Mako Surgical.
Stryker CEO Kevin Lobo says he doesn't view the so-called 'repless' generic sales models piloted by orthopedic rivals Smith & Nephew and Wright Medical as a serious threat.